Nonhuman Primate Model of Zika

Researchers infect rhesus macaques with the virus to better study its effects in humans.

Jun 28, 2016
Tanya Lewis

Rhesus macaquesWIKIMEDIA, ARINDAM ADITYAScientists have developed a nonhuman primate model of Zika virus infection to better understand its course in humans, especially in pregnant women. David O’Connor of the University of Wisconsin-Madison and colleagues injected eight rhesus macaques—two of them pregnant—with the Asian strain of the virus currently circulating in South and Central America. The non-pregnant and pregnant monkeys were still infected 21 days and up to 57 days later, respectively, and all animals were immune to reinfection 10 weeks post-injection, the researchers reported today (June 28) in Nature Communications. Prior to publication, the team was posting its data online in real time.

“This study in a nonhuman primate provides an important contribution to our understanding of the course of Zika virus infection in primates,” Amelia Pinto of Saint Louis University, Missouri, who was not involved in the work, said in a statement sent to reporters. However, “this study is ongoing, so from the results reported in this paper we cannot yet say that macaques are going to be a good model for understanding the links between Zika infection during pregnancy and the increased risk for microcephaly,” Pinto added.

In previous, unpublished work, O’Connor and colleagues infected two pregnant macaques with Zika during the animals’ third trimesters, sacrificed the fetuses at full term, and performed necropsies on them. The team did not observe evidence of microcephaly in the baby monkeys, but is still analyzing the aborted animals’ tissues. For the present study, the researchers infected pregnant monkeys during their first trimesters of pregnancy, as well as non-pregnant rhesus macaques (three males and three females).

With monkeys, “you can do experiments much more comprehensively than only with imaging in humans,” O’Connor said yesterday (June 27) during a press briefing.

The team detected the virus in the animals’ blood, urine, and saliva for up to 17 days post-injection. The virus was also found, for less than a week, in cerebrospinal fluid and vaginal fluid, the researchers wrote. None of the infected monkeys showed symptoms of Zika infection.

It’s unclear why the pregnant monkeys remained infected for longer than the non-pregnant ones. “Our leading hypothesis is it indicates the fetus is infected and is shedding virus back into mother’s bloodstream,” O’Connor told reporters during the briefing.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.